Advanced heart block and unresponsiveness after regadenoson administration during myocardial SPECT study

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages e49-e51

  Agarwal, Vikram ^a   DePuey, E Gordon ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Heart block; Regadenoson; SPECT study

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHYLLINE; AMLODIPINE; FUROSEMIDE; REGADENOSON; SIMVASTATIN; ADENOSINE A2 RECEPTOR AGONIST; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AGED; CASE REPORT; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAM; FAINTNESS; FEMALE; HEART BLOCK; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FAILURE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LETHARGY; LETTER; MYOCARDIAL PERFUSION IMAGING; PHARMACOLOGIC STRESS TESTING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT; SUBSTERNAL PAIN; T WAVE; VERY ELDERLY; CARDIAC GATED IMAGING; CHEMICALLY INDUCED; DIAGNOSTIC USE; PROCEDURES; SCINTISCANNING;

ADENOSINE A2 RECEPTOR AGONISTS; AGED, 80 AND OVER; CARDIAC-GATED SINGLE-PHOTON EMISSION COMPUTER-ASSISTED TOMOGRAPHY; FEMALE; HEART BLOCK; HUMANS; PURINES; PYRAZOLES;

EID: 84922403445     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.058     Document Type: Article

References (9)

1. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol Aug 2012; 19(4): 681-92. http://dx.doi.org/10.1007/s12350-12012-19547-12354.
2. http://www.drugcite.com/indi/?q=LEXISCAN& s=& a=& i=ATRIOVENTRICULAR? BLOCK?COMPLETE.
3. Pandit A, Unzek Freiman S. Complete heart block associated with regadenoson: A real side effect. J Nucl Cardiol Dec 2012; 19(6): 1236-9. http://dx.doi.org/10.1007/s12350-12012-19610-12351.
4. Eubany Jacqueline MH. Persistent complete heart block after administration of regadenoson. Paper Presented at: Heart Rhythm; May 09, 2013; 2013.
5. Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol Apr 2012; 19(2): 319-29.
6. Palani G, Husain Z, Salinas RC, Karthikeyan V, Karthikeyan AS, Ananthasubramaniam K. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. J Nucl Cardiol Aug 2011; 18(4): 605-11.
7. Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol Feb 2012; 19(1): 126-41.
8. Doukky R, RangelMO,WassoufM, Dick R, Alqaid A,Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation. J Nucl Cardiol Apr 2013; 20(2): 205-13.
9. Laighold S, Druz R. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patientwith end-stage renal disease on hemodialysis. J Nucl Cardiol May-Jun 2009; 16(3): 478-80.